LEADER 01620nam  2200457   450 
001 9910707237503321
005 20160622102658.0
035   $a(CKB)5470000002463134
035   $a(OCoLC)952027484
035   $a(OCoLC)995470000002463134
035   $a(EXLCZ)995470000002463134
100   $a20160622d2006      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aMedicare reimbursement for new end stage renal disease drugs
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2006.
215   $a1 online resource (iii, 8 pages)
300   $aTitle from title screen (viewed June 21, 2016).
300   $a"March 2006."
300   $a"OEI-03-06-00200."
320   $aIncludes bibliographical references.
517 1 $aMedicare reimbursement for new ESRD disease drugs
606   $aMedicare$xClaims administration
606   $aChronic renal failure$xTreatment$zUnited States$xFinance
606   $aDrugs$zUnited States$xCosts
606   $aPharmaceutical services insurance$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aMedicare$xClaims administration.
615  0$aChronic renal failure$xTreatment$xFinance.
615  0$aDrugs$xCosts.
615  0$aPharmaceutical services insurance
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707237503321
996   $aMedicare reimbursement for new end stage renal disease drugs$93310690
997   $aUNINA